ReviewTranslational cancer research2026
Optimizing the therapeutic ratio: a narrative review of de-escalation and response-adapted strategies in series including human papillomavirus negative head and neck cancer.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Head and neck cancer (HNC) treatments, primarily involving radiotherapy (RT) and chemoradiotherapy (CRT), often result in significant acute and late toxicities that profoundly impact patients' quality of life. Although there are data supporting treatment de-escalation for human papillomavirus (HPV)-positive HNC patients, there is growing interest in applying similar principles to HPV-negative disease in order to maintain oncologic efficacy while reducing treatment-related morbidity. This review aims to synthesize and critically appraise the current evidence regarding dose and/or volume de escalation strategies specifically implemented in the treatment of HPV-negative HNC. Methods: A search was conducted in SCOPUS and PubMed on June 30 Key Content and Findings: Six studies were included in this review. For HPV-negative head and neck squamous cell carcinoma (HNSCC), neoadjuvant nivolumab combined with chemotherapy enabled response-stratified de-escalated CRT, achieving favorable survival outcomes with reduced acute toxicities. In nasopharyngeal carcinoma (NPC), reduced intensity modulated radiotherapy (IMRT) target volumes following induction chemotherapy (IC) demonstrated non-inferior locoregional control (LRC) and significantly improved long-term quality of life, mitigating late toxicities such as xerostomia and hearing loss. Regarding elective nodal irradiation (ENI), studies confirmed that lower radiation doses maintained LRC while leading to clinically meaningful reductions in toxicity without increasing isolated regional recurrences (RRs). Conclusions: Dose and volume de-escalation appear feasible and beneficial in series that included HPV-negative HNSCC and NPC patients, maintaining oncologic efficacy while significantly reducing treatment-related toxicities. These findings expand the de-escalation paradigm beyond HPV-positive disease, offering a more tolerable therapeutic landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.